Evidence map›Paper›PMID 39653747›Full record

ArticleCell discovery2024

The comprehensive SARS-CoV-2 'hijackome' knowledge base.

Sini Huuskonen, Xiaonan Liu, Ina Pöhner, Taras Redchuk, Kari Salokas, Rickard Lundberg, Sari Maljanen, Milja Belik, Arttu Reinholm, Pekka Kolehmainen and 13 more

Abstract read
In one paragraph

Article in Cell discovery, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Skin as a Potential Entry Point for SARS-CoV-2 Virus.International journal of molecular sciences · 2026
    Article
  2. SKIN AS A POTENTIAL ENTRY POINT FOR SARS-COV-2.bioRxiv : the preprint server for biology · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. A Twist of Fate: The Helix-Turn-Helix Motif inJournal of chemical information and modeling · 2025
    Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Sini HuuskonenInstitute of Biotechnology, Helsinki Institute of Life Science HiLIFE, University of Helsinki, Helsinki, Finland.
Xiaonan LiuInstitute of Biotechnology, Helsinki Institute of Life Science HiLIFE, University of Helsinki, Helsinki, Finland.ORCID http://orcid.org/0000-0002-9600-0536
Ina PöhnerSchool of Pharmacy, University of Eastern Finland, Kuopio, Finland.
Taras RedchukInstitute of Biotechnology, Helsinki Institute of Life Science HiLIFE, University of Helsinki, Helsinki, Finland.
Kari SalokasInstitute of Biotechnology, Helsinki Institute of Life Science HiLIFE, University of Helsinki, Helsinki, Finland.ORCID http://orcid.org/0000-0002-4471-6698
Rickard LundbergInstitute of Biomedicine, University of Turku, Turku, Finland.
Sari MaljanenInstitute of Biomedicine, University of Turku, Turku, Finland.
Milja BelikInstitute of Biomedicine, University of Turku, Turku, Finland.ORCID http://orcid.org/0000-0002-4115-3922
Arttu ReinholmInstitute of Biomedicine, University of Turku, Turku, Finland.
Pekka KolehmainenInstitute of Biomedicine, University of Turku, Turku, Finland.
Antti TuhkalaInstitute of Biotechnology, Helsinki Institute of Life Science HiLIFE, University of Helsinki, Helsinki, Finland.
Garima TripathiInstitute of Biotechnology, Helsinki Institute of Life Science HiLIFE, University of Helsinki, Helsinki, Finland.
Pia LaineInstitute of Biotechnology, Helsinki Institute of Life Science HiLIFE, University of Helsinki, Helsinki, Finland.
Sergei BelanovInstitute of Biotechnology, Helsinki Institute of Life Science HiLIFE, University of Helsinki, Helsinki, Finland.
Petri AuvinenInstitute of Biotechnology, Helsinki Institute of Life Science HiLIFE, University of Helsinki, Helsinki, Finland.ORCID http://orcid.org/0000-0002-3947-4778
Maria VartiainenInstitute of Biotechnology, Helsinki Institute of Life Science HiLIFE, University of Helsinki, Helsinki, Finland.
Salla KeskitaloInstitute of Biotechnology, Helsinki Institute of Life Science HiLIFE, University of Helsinki, Helsinki, Finland.
Pamela ÖsterlundFinnish Institute for Health and Welfare, THL, Helsinki, Finland.ORCID http://orcid.org/0000-0002-2229-6661
Larissa LaineFinnish Institute for Health and Welfare, THL, Helsinki, Finland.
Antti PosoSchool of Pharmacy, University of Eastern Finland, Kuopio, Finland.
Ilkka JulkunenInstitute of Biomedicine, University of Turku, Turku, Finland.
Laura KakkolaInstitute of Biomedicine, University of Turku, Turku, Finland.
Markku VarjosaloInstitute of Biotechnology, Helsinki Institute of Life Science HiLIFE, University of Helsinki, Helsinki, Finland. markku.varjosalo@helsinki.fi.ORCID http://orcid.org/0000-0002-1340-9732

Funding

Academy of Finland (Suomen Akatemia) #336470
6 · The paper itself

Abstract

The continuous evolution of SARS-CoV-2 has led to the emergence of several variants of concern (VOCs) that significantly affect global health. This study aims to investigate how these VOCs affect host cells at proteome level to better understand the mechanisms of disease. To achieve this, we first analyzed the (phospho)proteome changes of host cells infected with Alpha, Beta, Delta, and Omicron BA.1 and BA.5 variants over time frames extending from 1 to 36 h post infection. Our results revealed distinct temporal patterns of protein expression across the VOCs, with notable differences in the (phospho)proteome dynamics that suggest variant-specific adaptations. Specifically, we observed enhanced expression and activation of key components within crucial cellular pathways such as the RHO GTPase cycle, RNA splicing, and endoplasmic reticulum-associated degradation (ERAD)-related processes. We further utilized proximity biotinylation mass spectrometry (BioID-MS) to investigate how specific mutation of these VOCs influence viral-host protein interactions. Our comprehensive interactomics dataset uncovers distinct interaction profiles for each variant, illustrating how specific mutations can change viral protein functionality. Overall, our extensive analysis provides a detailed proteomic profile of host cells for each variant, offering valuable insights into how specific mutations may influence viral protein functionality and impact therapeutic target identification. These insights are crucial for the potential use and design of new antiviral substances, aiming to enhance the efficacy of treatments against evolving SARS-CoV-2 variants.

Identifiers

PMID39653747
PMCPMC11628605

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.